JAK Inhibitor Dose TAPering Strategy Study

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

April 1, 2029

Study Completion Date

April 1, 2029

Conditions
Rhumatoid Arthisis
Interventions
DRUG

Baricitinib (LY3009104) 4 mg

"Treatment with baricitinib 4 mg daily~* Step 1 (after randomization): baricitinib 2mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day"

DRUG

filgotinib 200mg/day

"Treatment with filgotinib 200 mg daily~* Step 1 (after randomisation): filgotinib 100 mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day"

DRUG

Tofacitinib 5 mg twice daily

"Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily~* Step 1 (after randomisation): tofacitinib 5 mg once daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day"

DRUG

Upadacitinib 15 MG

"Treatment with upadacitinib 15 mg daily~* Step 1 (after randomisation): upadacitinib 15 mg every other day~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days"

DRUG

Baricitinib (LY3009104) 4 mg

use of JAK inhibitor at full dose until the end of the protocol

DRUG

filgotinib 200mg/day

use of JAK inhibitor at full dose until the end of the protocol

DRUG

Tofacitinib 5 mg twice daily

use of JAK inhibitor at full dose until the end of the protocol

DRUG

Upadacitinib 15 MG

use of JAK inhibitor at full dose until the end of the protocol

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER